DNAJB4与非小细胞肺癌免疫细胞浸润和患者预后的相关性分析

doi:10.3969/j.issn.1004-616x.2023.06.011

Abstract

Abstract: OBJECTIVE：To investigate expression of DNAJB4 in non-small cell lung cancer (NSCLC) and its association with immune cell infiltration levels and prognosis. METHODS：Differences in expression of DNAJB4 mRNA in cancer tissues of NSCLC patients and normal tissues adjacent to the cancers were evaluated based on GEPIA database analysis. Real-time quantitative PCR and immunohistochemical methods were used to detect expressions of DNAJB4 mRNA and protein in NSCLC tissues. The TIMER database was used to analyze correlations between the expression of DNAJB4 and the level of immune cells (B cells，CD4⁺T cells，CD8⁺T cells，neutrophils，macrophages，dendritic cells) infiltration in NSCLC，and to explore the prognosis of NSCLC patients with immune cell infiltration. Relationships between expression levels of DNAJB4 and prognosis of NSCLC were evaluated using the Kaplan Meier plot database. RESULTS：Expression of DNAJB4 in NSCLC tissues was lower than that of normal tissues. The low expression was associated with the infiltration levels of immune cells. In lung adenocarcinoma，copy number variations of DNAJB4 had a significant impact on the infiltration levels of immune cells (P<0.05). In addition，B cells served as independent prognostic factors for LUAD. In lung squamous cell carcinoma (LUSC)，DNAJB4 copy number variations had a significant impact on immune cell infiltration levels except for CD8⁺ T cells (P<0.05). Survival analysis showed a significant correlation between low expression of DNAJB4 and poor prognosis in NSCLC patients (P<0.05). CONCLUSION：DNAJB4 expression in NSCLC tissues was downregulated，involved in immune cell infiltration into cancer tissues，impacted on the balance of immune microenvironment，and adversely affected prognosis of the patients. DNAJB4 may be useful as a biological marker for immune cell infiltration and prognosis in NSCLC.

Key words: DNAJB4, non-small cell lung cancer, immune infiltration, prognosis

CLC Number:

R730.2

YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.

References

[1] KO E C,RABEN D,FORMENTI S C. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer[J]. Clin Cancer Res,2018,24(23):5792-5806.
[2] BABA Y,NOMOTO D,OKADOME K,et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma[J]. Cancer Sci,2020,111(9):3132-3141.
[3] 崔艺蒙,邢影,蔡莉. 肿瘤浸润性免疫细胞在肺癌微环境中的作用[J]. 肿瘤学杂志,2019,25(11):941-946.
[4] TAN X X,ZHANG X H,CHEN K,et al. The biologic properties of HLJ1 in hepatocellular carcinoma cells[J]. Int J Clin Exp Pathol,2017,10(3):2879-2886.
[5] LIU Y,ZHOU J,ZHANG C W,et al. HLJ1 is a novel biomarker for colorectal carcinoma progression and overall patient survival[J]. Int J Clin Exp Pathol,2014,7(3):969-977.
[6] ACUN T,DOBERSTEIN N,HABERMANN J K,et al. HLJ1(DNAJB4) gene is a novel biomarker candidate in breast cancer[J]. OMICS,2017,21(5):257-265.
[7] TANG Z F,LI C W,KANG B X,et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res,2017,45(W1):W98-W102.
[8] LI T W,FU J X,ZENG Z X,et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res,2020,48(W1):W509-W514.
[9] CHEN H W,LEE J Y,HUANG J Y,et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1[J]. Cancer Res,2008,68(18):7428-7438.
[10] SIM-ES-CORREIA J,SILVA D I,MELO S,et al. DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin,determining their fate in vitro and in vivo[J]. Hum Mol Genet,2014,23(8):2094-2105.
[11] MIAO W L,LI L,WANG Y S. A targeted proteomic approach for heat shock proteins reveals DNAJB4 as a suppressor for melanoma metastasis[J]. Anal Chem,2018,90(11):6835-6842.
[12] SHE K L,YU S Q,HE S S,et al. CircRNA 0009043 suppresses non-small-cell lung cancer development via targeting the miR-148a-3p/DNAJB4 axis[J]. Biomark Res,2022,10(1):61.
[13] FANG F,MO L L,PAN X F,et al. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway[J]. Discov Oncol,2023,14(1):40.
[14] MIAO W L,LI L,WANG Y S. A targeted proteomic approach for heat shock proteins reveals DNAJB4 as a suppressor for melanoma metastasis[J]. Anal Chem,2018,90(11):6835-6842.
[15] WAN H H,LIU Z H,TAN X X,et al. Application of immune cell infiltration in the diagnosis and prognosis of non-small cell lung cancer[J]. Chin J Biotechnol,2020,36(4):740-749.
[16] LARGEOT A,PAGANO G,GONDER S,et al. The B-side of cancer immunity:the underrated tune[J]. Cells,2019,8(5):449.
[17] NELSON B H. CD20+ B cells:the other tumor-infiltrating lymphocytes[J]. J Immunol,2010,185(9):4977-4982.

Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[2]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[3]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[4]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[5]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[6]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[7]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[8]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[9]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[10]	HU Xueyi, SHEN Feng, WU Lun, SU Caiwu, WEI Jian. SPON2 expression in papillary thyroid carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 9-14.
[11]	XU Hao, HU Bichuan, ZOU Wei, DUAN Yabin. Identification of prognostic factors among patients with stage Ⅲ gastric cancer undergoing radical resection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 30-36.
[12]	JIN Shuang, LI Kun, CHEN Hongrun, ZHANG Zhongmian. Prognostic value of PIV and AAPR in patients with non-small cell lung cancer with brain metastasis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 43-48.
[13]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.
[14]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[15]	QI Jiankao, TANG Xiao, SUN Shihui, KOU Yanfang, CUI Zhiqin. Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 366-372,403.